Silver Book Fact

Treatment for hypertension using antihypertensive therapy has generated a benefit-to-cost ratio of at least 6:1.

Cutler D, Long G, Berndt E, Royer J, et al. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler D, Long G, Berndt E, Royer J, et al.
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • Trends in carotid endarterectomy procedures  
  • In 2001, 86,000 more premature deaths from cardiovascular disease (50,000 men and 36,000 women) would have occurred among Americans age 40 and older without antihypertensive drug therapy.  
  • The rate of hospitalization from heart failure before and after transcatheter mitral valve repair (TMVR) decreases 73% (per patient year) in patients at prohibitive surgical risk.
     
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).